TOP TEN perturbations for 40067_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40067_at
Selected probe(set): 212420_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40067_at (212420_at) across 6674 perturbations tested by GENEVESTIGATOR:
DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)
Relative Expression (log2-ratio):3.702876Number of Samples:5 / 17
| Experimental | DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead) |
| Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they died from unknown reasons. | |
| Control | DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead) |
| Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they died from unknown reasons. |
DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive)
Relative Expression (log2-ratio):3.6147442Number of Samples:28 / 14
| Experimental | DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive) |
| Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they were alive. | |
| Control | DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive) |
| Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they were alive. |
DLBCL study 4 (ABC DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (ABC DLBCL; baseline; CHOP; alive)
Relative Expression (log2-ratio):3.4897041Number of Samples:54 / 19
| Experimental | DLBCL study 4 (ABC DLBCL; baseline; RCHOP; alive) |
| Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they were alive. | |
| Control | DLBCL study 4 (ABC DLBCL; baseline; CHOP; alive) |
| Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they were alive. |
DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead) / DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)
Relative Expression (log2-ratio):-3.342885Number of Samples:55 / 39
| Experimental | DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead) |
| Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons. | |
| Control | DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead) |
| Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons. |
DLBCL study 4 (GCB DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; alive)
Relative Expression (log2-ratio):3.244749Number of Samples:91 / 43
| Experimental | DLBCL study 4 (GCB DLBCL; baseline; RCHOP; alive) |
| Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they were alive. | |
| Control | DLBCL study 4 (GCB DLBCL; baseline; CHOP; alive) |
| Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they were alive. |
DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)
Relative Expression (log2-ratio):3.2232285Number of Samples:16 / 33
| Experimental | DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead) |
| Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons. | |
| Control | DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead) |
| Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.0089016Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.7724323Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinoma, NOS of the ovary (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
rheumatoid arthritis study 31 / TNF-ɑ study 20
Relative Expression (log2-ratio):2.552353Number of Samples:4 / 3
| Experimental | rheumatoid arthritis study 31 |
| Monocyte samples isolated from patients with rheumatoid arthritis (RA). Monocytes from whole blood were depleted from granulocytes by CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. Patients fulfilled the revised American College of Rheumatology criteria (ACR) for RA. | |
| Control | TNF-ɑ study 20 |
| Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. |
TC-71 / TC-32
Relative Expression (log2-ratio):2.4514914Number of Samples:6 / 6
| Experimental | TC-71 |
| Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code: | |
| Control | TC-32 |
| Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code: |